In this proposal, utilizing infection of cultured human muscle with BetaAPP or PrPC genes in adenovirus vector, we will pursue the following aims:
Aim 1. Determine whether long-term overexpression of BetaAPP or PrPc genes in normal human muscle cultured i) aneurally and ii) innervated, using adenovirus vector, will induce the IBM-phenotype, including a) vacuolization and the other aspects of IBM muscle degeneration b) PHFs, c) congophilic amyloid deposits and d) accumulation of the other IBM- characteristic proteins.
Aim 2. Determine whether increased ApoE in the muscle fiber (either by genetic overexpression through an adenovirus vector or by increased exposure from the culture medium) will facilitate development of the IBM phenotype in cultured normal human muscle concurrent with Beta APP and/or PrPc gene overexpression.
Aim 3 A. Determine whether challenging cultured h-IBM muscle aneurally or innervated with extra copies of the BetaAPP or PrPc gene will accelerate coordinated development in them of the IBM-phenotype and aggravate its severity, as compared to a) cultured uninfected h-IBM muscle and b) normal cultured human muscle with concurrently overexpressed BetaAPP and PrPc. (This is necessary because cultured uninfected h-IBM muscle fibers express some aspects of the IBM phenotype including increased accumulation of BetaAPP and PrPc, but this is present only in 20-40% of the muscle fibers at any given time -the severely affected fibers are dying while others do not yet express the phenotype).
Aim 3 B. Determine whether accumulation of ApoE (either by genetic expression thru an adenovirus vector or by exposure from the culture medium) will facilitate development of the IBM phenotype in cultured h-IBM muscle fibers without and with overexpressed BetaAPP or PrPc in them.
Aim 3 C. Determine whether infection of cultured h-IBM with adenovirus carrying BetaAPP or PrPc cDNA in antisense orientation will inhibit manifestation of the IBM phenotype. The broad objectives of our research are to better understand a) molecular mechanisms leading to increased accumulation in h- and s-IBM of a group of proteins that are normally not expressed extrajunctionally in adult human muscle, and b) their role in the disease process. Our long-term coals are to learn the molecular pathogenic mechanisms leading to h- and s-IBM which could eventually lead to treatment.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS034103-02
Application #
2037950
Study Section
Neurological Sciences Subcommittee 1 (NLS)
Program Officer
Baughman, Robert W
Project Start
1995-12-01
Project End
1998-11-30
Budget Start
1996-12-01
Budget End
1997-11-30
Support Year
2
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Southern California
Department
Neurology
Type
Schools of Medicine
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Askanas, Valerie; Engel, W King; Nogalska, Anna (2009) Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol 19:493-506
Askanas, Valerie; Engel, W King (2008) Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains. Acta Neuropathol 116:583-95
Askanas, Valerie; Engel, W King (2007) Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. Curr Opin Rheumatol 19:550-9
Engel, W King; Askanas, Valerie (2006) Inclusion-body myositis: clinical, diagnostic, and pathologic aspects. Neurology 66:S20-9
Askanas, Valerie; Engel, W King (2006) Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology 66:S39-48
Askanas, Valerie; Engel, W King (2003) Unfolding story of inclusion-body myositis and myopathies: role of misfolded proteins, amyloid-beta, cholesterol, and aging. J Child Neurol 18:185-90
Askanas, Valerie; Engel, W King (2003) Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-beta, misfolded proteins, predisposing genes, and aging. Curr Opin Rheumatol 15:737-44
Askanas, Valerie; Engel, W King (2002) Newest pathogenetic considerations in inclusion-body myositis: possible role of amyloid-beta, cholesterol, relation to aging and to Alzheimer's disease. Curr Rheumatol Rep 4:427-33
Askanas, Valerie; Engel, W King (2002) Inclusion-body myositis and myopathies: different etiologies, possibly similar pathogenic mechanisms. Curr Opin Neurol 15:525-31
Askanas, V; Engel, W K (2001) Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol 60:1-14

Showing the most recent 10 out of 17 publications